Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAB ULA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CAB ULA+ RPV ULA | EXPERIMENTAL | Participants will receive CAB ULA+RPV ULA. |
| CAB LA+ RPV LA | ACTIVE_COMPARATOR | Participants will receive CAB LA+RPV LA. |
| Name | Type | Description |
|---|---|---|
| CAB ULA | DRUG | CAB ULA will be administered. |
| RPV ULA | DRUG | RPV ULA will be administered. |
| CAB LA | DRUG | CAB LA will be administered. |
| RPV LA | DRUG | RPV LA will be administered. |
Inclusion criteria: Patient Study Participant (PSP) Inclusion criteria: * Adults and adolescents with HIV-1 infection aged 12 years or older with a weight \>35 kg. * Documented HIV-1 RNA measurements \<50 copies/mL in the 12 months prior to Screening. * HIV-1 RNA \<50 copies/mL at screening assess...
Top 20 of 28 competitors
CAB ULA, or cabotegravir ultra long-acting, is an investigational small molecule being studied for the treatment of HIV infections. It is being evaluated in combination with rilpivirine ultra long-acting (RPV ULA) in adults and adolescents with HIV who are virologically suppressed. The drug is currently in Phase 3 clinical development.
CAB ULA is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK is conducting a Phase 3 clinical trial to investigate the drug in combination with rilpivirine ultra long-acting for the treatment of HIV infections in virologically suppressed adults and adolescents.
CAB ULA is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 3 trial is recruiting participants to evaluate the safety and efficacy of CAB ULA in combination with rilpivirine ultra long-acting for HIV treatment.
CAB ULA is being studied in a Phase 3 clinical trial with the identifier NCT07650916. This randomized, active-controlled study is investigating cabotegravir ultra long-acting plus rilpivirine ultra long-acting in adults and adolescents with HIV who are virologically suppressed. The trial is recruiting 564 participants across multiple countries including the United States, Argentina, Australia, Canada, Japan, Mexico, Puerto Rico, Spain, and the United Kingdom.
CAB ULA is an integrase inhibitor, a class of antiretroviral drugs that block the HIV integrase enzyme, preventing the virus from integrating its genetic material into human DNA. This mechanism helps suppress viral replication. The drug is being studied as an ultra long-acting formulation for HIV treatment in combination with rilpivirine ultra long-acting.